Critical Comparison: Innocoll (INNL) and CoLucid Pharmaceuticals (CLCD)

Innocoll (NASDAQ: INNL) and CoLucid Pharmaceuticals (NASDAQ:CLCD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.


This table compares Innocoll and CoLucid Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innocoll -1,051.20% N/A -138.53%
CoLucid Pharmaceuticals N/A -83.51% -70.62%

Valuation and Earnings

This table compares Innocoll and CoLucid Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innocoll N/A N/A N/A ($1.66) -1.42
CoLucid Pharmaceuticals N/A N/A N/A ($3.43) -13.57

CoLucid Pharmaceuticals is trading at a lower price-to-earnings ratio than Innocoll, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

34.2% of Innocoll shares are owned by institutional investors. Comparatively, 64.2% of CoLucid Pharmaceuticals shares are owned by institutional investors. 13.7% of CoLucid Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for Innocoll and CoLucid Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innocoll 0 2 1 0 2.33
CoLucid Pharmaceuticals 0 3 1 0 2.25

Innocoll presently has a consensus price target of $3.00, indicating a potential upside of 27.66%. CoLucid Pharmaceuticals has a consensus price target of $47.83, indicating a potential upside of 2.80%. Given Innocoll’s stronger consensus rating and higher probable upside, equities analysts clearly believe Innocoll is more favorable than CoLucid Pharmaceuticals.


Innocoll beats CoLucid Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Innocoll Company Profile

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.

CoLucid Pharmaceuticals Company Profile

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Receive News & Ratings for Innocoll Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll and related companies with's FREE daily email newsletter.

Leave a Reply